Malte Peters

Malte Peters was appointed Chief Executive Officer in July 2024 and has served as a member of the Board of Directors of HOOKIPA since January 2023. Dr. Peters retired as Chief Research and Development Officer at MorphoSys at the end of 2022. He joined MorphoSys in 2017 as Chief Development Officer. In these roles, he oversaw the company’s research and development pipeline, including the design and execution of three pivotal studies. Prior to joining MorphoSys, Dr. Peters was Global Head of Clinical Development of the biopharmaceuticals business unit of Sandoz in Germany. Dr. Peters also spent 12 years in leadership positions at Novartis Oncology, including Vice President, Clinical Head and Site Head for Basel, East Hanover and Shanghai. He was responsible for multiple development programs and clinical trials at Novartis, contributing to the approval of several cancer therapies. Earlier in his career, he held positions at Micromet AG and Merck KgaA, and also served as a research scientist in infectious diseases.

Dr. Peters is a Member of the Board of Directors at Tango Therapeutics (NASDAQ: TNGX) and serves as Strategic Alliance Officer at EORTC (European Organisation for Research and Treatment of Cancer). He is board certified in internal medicine and earned his medical degree from Freie Universität in Berlin, with a postdoctoral fellowship in Toronto.